At the news
? NEUTRALIMPACT 5/10 8-K filed Nov 9, 2026 at 08:04 ET
Mentari Therapeutics (formerly InMed Pharmaceuticals) completed its merger with Mentari Therapeutics and closed $490M in private financings. The combined company trades under MTRI and has a clinical pipeline targeting migraine prevention with two lead candidates, MT-001 and MT-002.
- Merger between InMed Pharmaceuticals and Mentari Therapeutics closed on November 9, 2026
- Combined company renamed Mentari Therapeutics, Inc., trading under ticker MTRI on Nasdaq
- Private placement financings closed with gross proceeds of approximately $490 million
- Proceeds include conversion of $50.0 million of previously issued convertible notes plus accrued interest
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access